Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, announced it has launched Motiva® Implants in China.
“China is the second largest market globally, but has the opportunity to be much larger,” commented Juan José Chacón-Quirós, Establishment Labs Founder and Chief Executive Officer. “Establishment Labs was founded to make profound changes to our industry, and our growth reflects that. The Chinese market is unique in that the size of the opportunity is matched by both an appreciation among consumers for innovative technologies and a large segment willing to pay a premium for such products. Not only do we expect China to quickly become one of the largest and fastest growing segments for our company, we also expect to expand the market in China as women are introduced to new standards and possibilities.”
Dr. Chen Yuzhe, a senior plastic surgeon at BCC Beijing added, “We all look forward to Motiva’s brilliant performance here in China and it will inject new vitality into the development of our plastic surgery and beauty industry.”
The commercial launch coincided with the Motiva China International Academic Conference that was held in Hainan, China; events also took place in Shanghai, Guangzhou, and Shenzhen. Establishment Labs received National Medical Products Administration (NMPA) approval in China for Motiva® Implants in November 2023.
